Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell 4.4% during trading on Wednesday . The company traded as low as $41.44 and last traded at $42.13, with a volume of 255,001 shares traded. The stock had previously closed at $44.05.

A number of research firms recently commented on AGIO. Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Sunday, March 27th. Goldman Sachs Group Inc. reiterated a “hold” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, June 13th. Janney Montgomery Scott reiterated a “neutral” rating and issued a $47.00 target price (down from $52.00) on shares of Agios Pharmaceuticals in a research report on Monday, June 13th. Leerink Swann reiterated a “market perform” rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, May 19th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $50.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, May 18th. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $69.67.

The company’s 50-day moving average price is $49.57 and its 200-day moving average price is $46.53. The firm’s market cap is $1.55 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.18. The business had revenue of $31.30 million for the quarter, compared to analyst estimates of $20.94 million. During the same quarter last year, the business earned ($0.13) earnings per share. Agios Pharmaceuticals’s revenue was down 8.5% on a year-over-year basis. Equities analysts forecast that Agios Pharmaceuticals Inc. will post ($3.46) EPS for the current year.

In related news, Director Lewis Clayton Jr. Cantley sold 627 shares of Agios Pharmaceuticals stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $40.37, for a total value of $25,311.99. Following the sale, the director now directly owns 125,921 shares in the company, valued at approximately $5,083,430.77. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Scott Biller sold 27,500 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total value of $1,787,500.00. Following the completion of the sale, the insider now owns 81,376 shares in the company, valued at $5,289,440. The disclosure for this sale can be found here.

A number of large investors have recently bought and sold shares of AGIO. Jennison Associates LLC boosted its stake in Agios Pharmaceuticals by 170.6% in the fourth quarter. Jennison Associates LLC now owns 430,085 shares of the biopharmaceutical company’s stock valued at $27,921,000 after buying an additional 271,142 shares during the last quarter. BB Biotech AG raised its position in Agios Pharmaceuticals by 2.4% in the fourth quarter. BB Biotech AG now owns 2,159,921 shares of the biopharmaceutical company’s stock worth $140,222,000 after buying an additional 50,000 shares during the period. Alps Advisors Inc. acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $3,219,000. Columbia Wanger Asset Management LLC raised its position in Agios Pharmaceuticals by 11.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 436,994 shares of the biopharmaceutical company’s stock worth $28,370,000 after buying an additional 44,861 shares during the period. Finally, GAM Holding AG raised its position in Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock worth $2,967,000 after buying an additional 31,000 shares during the period.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.